NCT05472220View on ClinicalTrials.gov

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 1, 2022

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Solid Tumors, AdultPIK3CA Mutation-Related TumorsPIK3CA MutationHuman Papillomavirus-Related CarcinomaHPV-Related Squamous Cell CarcinomaHuman Papillomavirus-Related Squamous Cell CarcinomaLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
Interventions
DRUG

Alpelisib

Given orally

DRUG

Carboplatin

Given IV during imaging

DRUG

Hyperpolarized Carbon-13 (13C) Pyruvate

Given IV

DEVICE

Continuous Glucose Monitor (CGM)

Self-applied devices that sit partially beneath the skin

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Pamela Munster

OTHER